Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease

Area of Science:

• Nephrology and Cardiovascular Medicine

Background:

• Chronic kidney disease (CKD) drastically reduces life expectancy, with cardiovascular disease (CVD) as the primary cause of mortality in pediatric patients.
• Unlike general populations, CKD-associated CVD involves vascular endothelial dysfunction, medial arterial calcification, and cardiac dysfunction, often without traditional risk factors.
• The mechanisms driving these vascular pathologies in CKD, including vascular smooth muscle cell to osteoblast-like transition and altered bone/mineral metabolism, are not fully understood.

Purpose of the Study:

• To elucidate the complex pathogenesis of cardiovascular complications in chronic kidney disease.
• To investigate the role of bone and mineral metabolism in CKD-associated cardiovascular disease progression.
• To identify optimal therapeutic strategies for mitigating cardiovascular dysfunction, vascular calcification, and premature mortality in CKD patients.

Main Methods:

• Review of existing literature on CKD pathophysiology and cardiovascular complications.
• Analysis of the mechanisms linking vascular calcification, bone/mineral metabolism, and cardiovascular events in CKD.
• Evaluation of current therapeutic approaches for renal osteodystrophy and their impact on cardiovascular outcomes.

Main Results:

• Cardiovascular disease in CKD arises from distinct pathways including vascular calcification and dysfunction, differing from general population atherosclerosis.
• Altered bone and mineral metabolism, particularly vascular smooth muscle cell transition, are key contributors to progressive cardiovascular disease in CKD.
• Existing therapies for renal osteodystrophy show some impact but do not fully address the early origins of CVD in CKD.

Conclusions:

• Cardiovascular disease in CKD is multifactorial, involving unique vascular pathologies and metabolic derangements.
• Therapeutic interventions targeting bone and mineral metabolism influence cardiovascular disease progression in CKD patients.
• Optimal treatment strategies are needed to address the early development of cardiovascular complications and reduce mortality in CKD.